The concentration of LEAP2 in human milk and infant plasma is positively associated with adiposity and body weight in the first year of life.

LEAP2 infant adiposity infant body weight lactation milk hormones

Journal

The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243

Informations de publication

Date de publication:
12 Sep 2024
Historique:
received: 19 04 2024
revised: 30 08 2024
accepted: 06 09 2024
medline: 15 9 2024
pubmed: 15 9 2024
entrez: 14 9 2024
Statut: aheadofprint

Résumé

The liver-expressed antimicrobial peptide 2 (LEAP2) is a recently recognized anorectic and glucose-regulating hormone, with unknown role in lactation. 1) Assess LEAP2 presence in human milk and putative associations with infant body weight and adiposity in the first year of life, 2) Evaluate the impact of maternal weight status on LEAP2 concentration and 3) Explore the relationship between infant plasma LEAP2 concentration and body weight and adiposity. This prospective cohort observational study assessed LEAP2 concentration in plasma and milk from lactating women with normal weight (n=26) or overweight/obesity (OW/OB, n=26) at six months postpartum and in 6-month-old infant plasma, examining associations with metabolic and anthropometric variables at 6 months and 1 year. Maternal plasma and milk leptin and insulin concentrations were also measured. LEAP2 expression in milk fat globules and single-cell-RNA-sequencing datasets was evaluated. LEAP2 was detected in all milk samples assessed (2.08±0.65 ng/ml) and was positively associated with infant triceps (p=0.022, Cohen f Milk LEAP2 is a bioactive component that plays a role in infant fat accretion in the first year of life. While maternal LEAP2 responds to weight change in pregnancy and lactation, infant plasma LEAP2 might be involved in body weight regulation in early life. This study was registered at clinicaltrials.gov as NCT05798676. https://clinicaltrials.gov/study/NCT05798676.

Sections du résumé

BACKGROUND BACKGROUND
The liver-expressed antimicrobial peptide 2 (LEAP2) is a recently recognized anorectic and glucose-regulating hormone, with unknown role in lactation.
OBJECTIVES OBJECTIVE
1) Assess LEAP2 presence in human milk and putative associations with infant body weight and adiposity in the first year of life, 2) Evaluate the impact of maternal weight status on LEAP2 concentration and 3) Explore the relationship between infant plasma LEAP2 concentration and body weight and adiposity.
METHODS METHODS
This prospective cohort observational study assessed LEAP2 concentration in plasma and milk from lactating women with normal weight (n=26) or overweight/obesity (OW/OB, n=26) at six months postpartum and in 6-month-old infant plasma, examining associations with metabolic and anthropometric variables at 6 months and 1 year. Maternal plasma and milk leptin and insulin concentrations were also measured. LEAP2 expression in milk fat globules and single-cell-RNA-sequencing datasets was evaluated.
RESULTS RESULTS
LEAP2 was detected in all milk samples assessed (2.08±0.65 ng/ml) and was positively associated with infant triceps (p=0.022, Cohen f
CONCLUSIONS CONCLUSIONS
Milk LEAP2 is a bioactive component that plays a role in infant fat accretion in the first year of life. While maternal LEAP2 responds to weight change in pregnancy and lactation, infant plasma LEAP2 might be involved in body weight regulation in early life.
CLINICAL TRIAL REGISTRY BACKGROUND
This study was registered at clinicaltrials.gov as NCT05798676. https://clinicaltrials.gov/study/NCT05798676.

Identifiants

pubmed: 39277116
pii: S0022-3166(24)01025-3
doi: 10.1016/j.tjnut.2024.09.008
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT05798676']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society for Nutrition. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Auteurs

Ana Luz Kruger (AL)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina; CONICET. La Plata, Buenos Aires, Argentina.

Agustina Malpeli (A)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina.

Marisa Sala (M)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina.

Carla Casado (C)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina.

Ignacio Mendez (I)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina.

Lucrecia Fotia (L)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina.

Mercedes López (M)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina.

Andrea Tournier (A)

Laboratorio Central, Children´s Hospital HIAEP "Sor María Ludovica" La Plata. La Plata, Buenos Aires, Argentina.

Daniel Castrogiovanni (D)

Neurophysiology Group - Instituto Multidisciplinario de Biología Celular (IMBICE) (UNLP - CIC-PBA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)). La Plata, Argentina.

Florencia Heredia (F)

Neurophysiology Group - Instituto Multidisciplinario de Biología Celular (IMBICE) (UNLP - CIC-PBA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)). La Plata, Argentina.

Ramiro Llovera (R)

Neurophysiology Group - Instituto Multidisciplinario de Biología Celular (IMBICE) (UNLP - CIC-PBA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)). La Plata, Argentina.

Helgi B Schiöth (HB)

Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.

Mario Perello (M)

Neurophysiology Group - Instituto Multidisciplinario de Biología Celular (IMBICE) (UNLP - CIC-PBA - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)). La Plata, Argentina; Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden. Electronic address: mperello@imbice.gov.ar.

María F Andreoli (MF)

Instituto de Desarrollo e Investigaciones Pediátricas (IDIP). Children´s Hospital HIAEP "Sor María Ludovica" La Plata - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA). La Plata, Buenos Aires, Argentina; CONICET. La Plata, Buenos Aires, Argentina; Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden. Electronic address: mfandreoli@conicet.gov.ar.

Classifications MeSH